Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ8QW7
|
|||
| Drug Name |
PF-07284890
|
|||
| Synonyms |
Tinlorafenib; ARRY-461; Tinlorafenib [USAN]; PF-07284890; JNJ5N2RH5W; AR00504461; UNII-JNJ5N2RH5W; 2573781-75-4; WHO 12353; 1-Propanesulfonamide, N-(2-chloro-3-((3,4-dihydro-3,5-dimethyl-4-oxo-6-quinazolinyl)amino)-4-fluorophenyl)-3-fluoro-; N-(2-chloro-3-((3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide; tinlorafenib [INN]; ARRY461; CHEMBL5095256; SCHEMBL22831935; GTPL12096; BDBM565133; EX-A7593; HY-147405; CS-0564141; PF07284890; PF-07284890; ARRY-461; US11414404, Ex. # 10
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [1] | |
| Company |
Pfzer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H19ClF2N4O3S
|
|||
| Canonical SMILES |
CC1=C(C=CC2=C1C(=O)N(C=N2)C)NC3=C(C=CC(=C3Cl)NS(=O)(=O)CCCF)F
|
|||
| InChI |
InChI=1S/C19H19ClF2N4O3S/c1-11-13(6-7-14-16(11)19(27)26(2)10-23-14)24-18-12(22)4-5-15(17(18)20)25-30(28,29)9-3-8-21/h4-7,10,24-25H,3,8-9H2,1-2H3
|
|||
| InChIKey |
VVLVISDSGRHLMB-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04543188) A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF-07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Pfzer | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.